CreativeOne Wealth LLC Invests $869,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CreativeOne Wealth LLC acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 39,413 shares of the company's stock, valued at approximately $869,000.

Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $58,243,000. Raymond James Financial Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $38,914,000. Finally, Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $38,550,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TEVA shares. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Finally, Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $0.35 during trading on Monday, hitting $13.30. 12,058,632 shares of the stock were exchanged, compared to its average volume of 9,911,345. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The stock has a fifty day moving average price of $15.45 and a two-hundred day moving average price of $17.67. The firm has a market capitalization of $15.08 billion, a P/E ratio of -9.17, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.